Clinical Trial Update: Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Melaxin cancer vaccine plus Bacillus Calmette-Guérin (BCG) for malignant melanoma was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) vaccine (Bacillus Calmette-Guérin vaccine)
• Melaxin cancer vaccine (Melaxin cancer vaccine)

Snippet

Sponsor: Prisma Health-Upstate | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-06-04